Table 2.
Geometric mean (95% CI) Titer by OPA of Ig Antibody at baseline, 4, 12 and 24 months after immunization.
| Serotypes | Baseline | M4 | M12 | M24 | |
|---|---|---|---|---|---|
| 4 | NR | 9.8 (4.4–21.5) | 41.7 (25–69.4) | 18.7 (7.7–45.4) | 32.2 (11.8–88) |
| R | 4.2 (1.2–15.2) | 120.4 (28.8–503.2) | 42.2 (12.2–146.1) | 14.5 (3.0–71.2) | |
| 6B | NR | 31 (10.9–88.6) | 132.2 (63.8–274.2) | 96.9 (44–213.1) | 60.5 (15.7–234) |
| R | 13.9 (1.2–166.2) | 178.1 (26.1–1216) | 119.9 (27.1–530) | 29.7 (1.3–705.2) | |
| 9V | NR | 27.2 (11.1–66.6) | 58 (27.6–122) | 31.7 (11.1–90.8) | 41.9 (11.8–148.6) |
| R | 15.6 (2.5–99.2) | 79.2 (16.7–375.5) | 41.1 (6.8–248.8) | 17.2 (1.5–199) | |
| 14 | NR | 86.1 (31.3–236.6) | 145.5 (63.8–331.6) | 124 (49–314) | 59.1 (12.3–284.4) |
| R | 11.2 (1.2–102.9) | 137.6 (24.3–779.7) | 61.3 (6.3–598.5) | 25.8 (2.2–302.5) | |
| 18C | NR | 55.7 (20.4–152.3) | 89.7 (36.6–220) | 74.4 (29.1–190.2) | 51.2 (8.8–298.5) |
| R | 9.3 (1.4–61.5) | 118.1 (18.4–758.9) | 23.2 (2.2–244.8) | 13.1 (0.9–186.3) | |
| 19F | NR | 57.2 (26.5–123.3) | 188.7$ (89.5–397.5) | 125.1 (62.5–250.2) | 87.2 (18.8–405.6) |
| R | 28.5 (11.8–68.8) | 200.5$ (68.9–582.9) | 131.8$ (35.1–494.7) | 46.2 (4.5–475.8) | |
| 23F | NR | 19 (7.1–51.2) | 29.1 (9.2–91.7) | 27.8 (8.6–89.3) | 18.5 (3.2–107.5) |
| R | 5.4 (1–29) | 45.3 (7.1–287.1) | 12.6 (2.5–63.8) | 4.7 (1.1–20.7) | |
Note: Responders at four month were defined as at least a four-fold increased from baseline. Data are in geometric means: Opsonisation titer (95% confidence limits). R: Reponders group, NR: Non-reponders group,
$
p<0.05 vs. baseline